Cell-free DNA integrity for the monitoring of breast cancer:Future perspectives?  

作　　者：Navid Sobhani Daniele Generali Fabrizio Zanconati Marina Bortul Bruna Scaggiante 

机构地区：[1]Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Academic Hospital [2]Department of Life Sciences, University of Trieste

出　　处：《World Journal of Clinical Oncology》2018年第2期26-32,共7页世界临床肿瘤学杂志（英文版）

基　　金：Supported by Ricerca Sanitaria 2015 LILT and Beneficentia Foundation Stiftung,No.BEN2016/16

摘　　要：Breast cancer(BC) is the most common cancer and the second cause of death in women worldwide. Therapeutic options are increasing, but the response to treatments is not always efficient and the risk of recurrence covers decades. In this perspective, the need to have a proper follow-up for the therapeutic responses and for anticipating recurrence it is urgent in the clinical setting. Liquid biopsy provides the basic principle for a non-invasive method for the routinely monitoring of BC. However, due to the heterogeneity of tumors during onset and progression, the search for tumor DNA mutations of targeted genes in plasma/serum is a limiting factor. A possible approach overtaking this problem comes from the measurement of cell-free DNA integrity, which is an independent factor from the mutational status and theoretically is representative of all tumors. This review summarizes the state-of-the-art of cell-free DNA integrity researches in BC, the controversies and the future perspective.Breast cancer(BC) is the most common cancer and the second cause of death in women worldwide. Therapeutic options are increasing, but the response to treatments is not always efficient and the risk of recurrence covers decades. In this perspective, the need to have a proper follow-up for the therapeutic responses and for anticipating recurrence it is urgent in the clinical setting. Liquid biopsy provides the basic principle for a non-invasive method for the routinely monitoring of BC. However, due to the heterogeneity of tumors during onset and progression, the search for tumor DNA mutations of targeted genes in plasma/serum is a limiting factor. A possible approach overtaking this problem comes from the measurement of cell-free DNA integrity, which is an independent factor from the mutational status and theoretically is representative of all tumors. This review summarizes the state-of-the-art of cell-free DNA integrity researches in BC, the controversies and the future perspective.

关 键 词：cfDNA INTEGRITY Liquid BIOPSY BREAST cancer ALU SEQUENCES LINE-1 SEQUENCES 

分 类 号：R[医药卫生]